The global Stone Disease Market is projected to grow significantly during 2024-2031, driven by rising cases of kidney, bladder, and urinary stones. Key players include Boston Scientific, Becton Dickinson, and Calyxo, which secured $32.7 million in funding in 2022. The market report highlights advancements in treatment technologies, such as Boston Scientific's FDA-cleared LithoVue Elite ureteroscope system and Calyxo's CVAC Aspiration System. Regional analysis covers North America, Europe, Asia-Pacific, and others, with a focus on market dynamics, regulatory factors, and competitive strategies.

CalciMedica Inc. announced significant findings from its CARDEA trial, showing a substantial reduction in mortality among acute kidney injury (AKI) patients treated with Auxora. The company presented data at the 30th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference, demonstrating a 62.7% relative decrease in mortality at day 30, sustained through day 60, in patients with AKI and respiratory failure. Dr. Sudarshan Hebbar highlighted the potential of CRAC channel inhibition as a therapeutic mechanism for AKI. The company is also advancing its Phase 2 KOURAGE trial and a Phase 1/2 trial in pediatric patients with asparaginase-induced pancreatic toxicity. Concurrently, CalciMedica announced the appointment of Dr. Alan Glicklich to its board, following Eric Bjerkholt's resignation.

KalVista Pharmaceuticals, Inc. has received Orphan Drug Designation from Japan's Ministry of Health, Labour and Welfare for its HAE treatment sebetralstat. The company has submitted a New Drug Application in Japan, based on the KONFIDENT phase 3 trial results. Analysts predict significant sales potential for sebetralstat, with TD Cowen projecting over $750 million in peak sales.

Innovative Medical Products, Inc. (IMP) and Curexo Inc. have formed a global strategic distribution partnership where Curexo will integrate IMP's De Mayo D2® Knee Positioner with its CUVIS-joint robot for hospitals outside the U.S. The collaboration aims to enhance surgical patient care worldwide.

The report on the Asia-Pacific Surgical Robotics Market projects a compound annual growth rate (CAGR) of 17.29% from 2022 to 2032. It segments the market into Surgical Systems, Instruments and Accessories, and Services, focusing on applications like General Surgery and Cardiology Surgery. The document provides insights for stakeholders to drive strategic developments and facilitates market navigation with a focus on partnerships and collaborations.